Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 210-217

  Hervier, Baptiste ^a,b   Devilliers, Hervé ^c   Stanciu, Raluca ^a,b   Meyer, Alain ^d   Uzunhan, Yurdagul ^e   Masseau, Agathe ^f   Dubucquoi, Sylvain ^g   Hatron, Pierre Yves ^g   Musset, Lucile ^a,b   Wallaert, Benoit ^g   Nunes, Hilario ^e   Maisonobe, Thierry ^a,b   Olsson, Nils Olivier ^c,d   Adoue, Daniel ^h   Arlet, Philippe ^h   Sibilia, Jean ^d   Guiguet, Marguerite ^b   Lauque, Dominique ^h   Amoura, Zahir ^a,b   Hachulla, Eric ^g   Hamidou, Mohamed ^f   Benveniste, Olivier ^a,b   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e AVICENNE HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Anti tRNA synthetase antibody; Clustering analysis; Interstitial lung disease; Myositis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AZATHIOPRINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; JO 1 ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ANTIBODY SPECIFICITY; ANTISYNTHETASE SYNDROME; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOSITIS; PHENOTYPE; RETROSPECTIVE STUDY; REVIEW; SURVIVAL;

ADULT; AMINO ACYL-TRNA SYNTHETASES; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CLUSTER ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS; PHENOTYPE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84870239668     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.06.006     Document Type: Review

References (29)

1. Love L.A., Leff R.L., Fraser D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70(6):360-374.
2. Marguerie C., Bunn C.C., Beynon H.L., et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990, 77(282):1019-1038.
3. Dugar M., Cox S., Limaye V., Blumbergs P., Roberts-Thomson P.J. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 2011, 41(9):674-679.
4. Ghillani P., Andre C., Toly C., Rouquette A.M., Bengoufa D., Nicaise P., et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 2011, 10(9):509-513.
5. Ronnelid J., Barbasso Helmers S., Storfors H., Grip K., Rönnblom L., Franck-Larsson K., et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 2009, 9(1):58-61.
6. La Corte R., Lo Mo N.A., Locaputo A., Dolzani F., Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006, 39(3):249-253.
7. Marie I., Hatron P.Y., Dominique S., Cherin P., Mouthon L., Menard J.F., et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 Antibody. Semin Arthritis Rheum 2012, 41(6):890-899.
8. Marie I., Josse S., Decaux O., Dominique S., Diot E., Landron C., et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012, Feb 3 [Epub ahead of print].
9. Hervier B., Wallaert B., Hachulla E., Adoue D., Lauque D., Audrain M., et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford) 2010, 49(5):972-976.
10. Hervier B., Uzunhan Y., Hachulla E., Benveniste O., Nunes H., Delaval P., et al. Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur Respir J 2011, 37(3):714-717.
11. Kalluri M., Sahn S.A., Oddis C.V., Gharib S.L., Christopher-Stine L., Danoff S.K., et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009, 135(6):1550-1556.
12. Yamasaki Y., Yamada H., Nozaki T., Akaogi J., Nichols C., Lyons R., et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006, 54(6):2004-2009.
13. Marie I., Hatron P.Y., Dominique S., Cherin P., Mouthon L., Menard J.F. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011, 63(11):3439-3447.
14. Mimori T., Imura Y., Nakashima R., Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007, 19(6):523-529.
15. Spath M., Schroder M., Schlotter-Weigel B., Walter M.C., Hautmann H., Leinsinger G., et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 2004, 251(7):859-864.
16. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292(8):403-407.
17. Kendall F.P., Mc Creary E.K., Provenance P.G., Rodgers M.M., Romani W.A. Mucles: testing & function 2005, Williams & Vilkins, Baltimore. 5th edn.
18. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161(2 Pt 1):646-664.
19. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61(6):554-558.
20. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34(6):1219-1263.
21. Izenman AJ. Modern Multivariate Statistical Techniques: Regression, Classification, and Manifold Learning. illustrated edn 2008 ed. Springer-Verlag, New-York inc.; 2008.
22. Friedman A.W., Targoff I.N., Arnett F.C. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996, 26(1):459-467.
23. Watanabe K., Handa T., Tanizawa K., Hosono Y., Taguchi Y., Noma S., et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med 2011, 105(8):1238-1247.
24. Sharp G.C., Irvin W.S., Tan E.M., Gould R.G., Holman H.R. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972, 52(2):148-159.
25. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
26. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28(7):1573-1576.
27. Connors G.R., Christopher-Stine L., Oddis C.V., Danoff S.K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest 2010, 138(6):1464-1474.
28. Yoshifuji H., Fujii T., Kobayashi S., Imura Y., Fujita Y., Kawabata D., et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006, 39(3):233-241.
29. Tillie-Leblond I., Wislez M., Valeyre D., Crestani B., Rabbat A., Israel-Biet D., et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008, 63(1):53-59.